Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
Surya P. Bhatt(University of Alabama at Birmingham), Lacey B. Robinson(Sanofi (France)), Déborah Bauer(Wellesley College), Elizabeth Laws(Sanofi (United States)), Mona Bafadhel(National Institute for Health and Care Research), Nicola A. Hanania(Baylor College of Medicine), Jennifer Maloney(Regeneron (United States)), Klaus F. Rabe(Christian-Albrechts-Universität zu Kiel), Alberto Papi(University of Ferrara), Claus Vogelmeier(German Center for Lung Research), Dave Singh(Manchester University NHS Foundation Trust), Bolanle Akinlade(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Ashish Bansal(Regeneron (United States)), Xin Lu(Sanofi (United States)), Naimish Patel(Sanofi (United States)), Raolat M. Abdulai(Sanofi (United States)), Stephanie A. Christenson(University of California, San Francisco)
Cited by 240
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k